ArticleAddiction science & clinical practice2020
Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach.
Article in Addiction science & clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis.Addiction science & clinical practice · 2022Pooled it
- Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review.Pharmacotherapy · 2022Pooled it
- Barriers to Buprenorphine Initiation in Patients Using Fentanyl.JAMA network open · 2026Article
- Emergency department management of opioid use disorder in pediatric patients.Journal of the American College of Emergency Physicians open · 2024Article
- Low-dose overlap initiation with split tablets of buprenorphine in intubated intensive care unit patients with opioid use disorder.Harm reduction journal · 2024Article
- Low-Dose Initiation of Buprenorphine: A Narrative Review.Current pain and headache reports · 2023Review
- Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series.Addiction science & clinical practice · 2023Article
- Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia.Addiction (Abingdon, England) · 2022Article
- Treating Chronic Pain with Buprenorphine-The Practical Guide.Current treatment options in oncology · 2021Review
- The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder.Clinical drug investigation · 2021Review
- Retention in the Austrian opioid agonist treatment system: a national prospective cohort study.Harm reduction journal · 2021Article
- Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial.Addiction science & clinical practice · 2021Article
- Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients-A Critical Review.Frontiers in pharmacology · 2021Review
- Using Microdosing to Induct Patients Into a Long-Acting Injectable Buprenorphine Depot Medication in Low Threshold Community Settings: A Case Study.Frontiers in pharmacology · 2021Article
- Balancing transition and readmission: a comparative study of low-dose vs standard buprenorphine initiation for medically managed opioid withdrawal.Journal of addictive diseasesArticle
- Uptake of Low-dose Buprenorphine Initiation and Associated Patient Characteristics in British Columbia, Canada: A Population-based Cohort Study.Journal of addiction medicineArticle
- Intravenous Buprenorphine Micro-dosing Induction in a Patient on Methadone Treatment: A Case Report.Journal of the Academy of Consultation-Liaison PsychiatryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe requirement for moderate withdrawal prior to initiation can be a barrier to buprenorphine/naloxone induction. CASE PRESENTATION: We aimed to use a microdosing regimen to initiate regular dosing of buprenorphine/naloxone in a high-risk patient with a history of failed initiations due, in part, to withdrawal symptoms. Using an assertive outreach model and a buprenorphine/naloxone microdosing schedule, we initiated treatment of an individual's opioid use disorder. There was a successful buprenorphine/naloxone microdosing induction as the team reached a therapeutic dose of buprenorphine/naloxone. Including the induction period, the medication was used consistently for 4 weeks.
conclusionsA microdosing schedule can be used to induce a patient onto buprenorphine/naloxone with no apparent withdrawal; gradually reducing illicit substance use. This case report builds on previous literature, highlighting ways to minimize barriers to induction of buprenorphine/naloxone, using a microdosing schedule and assertive outreach. Given the safety profile of buprenorphine and its potential to be a lifesaving intervention, a larger study of microdosing is indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.